Skip to main content
. Author manuscript; available in PMC: 2015 Jan 26.
Published in final edited form as: Clin Lung Cancer. 2010 Nov 1;11(6):405–411. doi: 10.3816/CLC.2010.n.052

Figure 5. Intratracheal Administration of Low-Dose 5-Azacytidine Significantly Prolongs Survival of Mice Bearing Orthotopic Human NSCLC Xenografts.

Figure 5

Mice intratracheally inoculated with H358 (A) or H460 (B) human NSCLC cell lines were treated with I.V. or I.T. 5-Aza on day 10 at a dose of 6.25 mg/kg daily × 6 for I.V. and 2.5 mg/kg every other day × 3 for I.T. The control was a group of untreated mice (thin line).

Abbreviations: 5-Aza = 5-azacytidine; I.T. = intratracheal injection; I.V. = intravenous injection; NSCLC = non–small-cell lung cancer